Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review covers recent advances in prostate cancer risk assessment, diagnosis, and treatment but does not report new clinical results; further studies on androgen deprivation therapy's cardiovascular risks are particularly noted.

This study highlights cases of alopecia areata that developed during anti-TNF-α therapy, suggesting a potential link or increased frequency, particularly among individuals with a personal or family history of autoimmune diseases.

This study reported that an ATRA-loaded nanostructured lipid carrier gel (ATRA-NLC-Gel) improved symptoms of alopecia areata in mice by enhancing transdermal drug delivery, reducing skin irritation, and promoting hair regrowth through targeted follicle enrichment and pathway activation.

In this animal study, atorvastatin co-administered with trastuzumab reversed trastuzumab-induced cognitive impairment (chemo-brain) and improved its anti-cancer efficacy without causing hair loss.

This study found that adding allergen immunotherapy to conventional treatment may reduce relapse-related hair loss in house dust mite-allergic alopecia areata patients over a 3-year period.

This study developed a rapid ATP assay that effectively measures microbial populations on the skin and tracks changes after microbiome dysbiosis, with findings suggesting that ethanol-cleansed skin takes longer to recover than tape-stripped skin.

This source explains that unlike genetic hormonal alopecia, alopecia areata is associated with inflammatory factors and may also involve psychological and genetic contributions.

This review discusses traction alopecia in individuals with Afro-textured hair and emphasizes the importance of education to prevent this condition, but it reports no new clinical results.

In this study, gelatin-coated transferosomes were developed to deliver tofacitinib specifically to hair follicles, resulting in 80% hair regrowth in alopecia areata patients with recalcitrant lesions after 12 weeks of treatment.

This case report described a 24-year-old with alopecia totalis who saw full scalp hair regrowth by the 9th month while using oral tofacitinib, which was well-tolerated and did not show serious adverse effects. Longer-term studies are needed to confirm its overall effectiveness for alopecia totalis.

This study observed that patients with alopecia areata have a significantly higher prevalence of thyroid disorders and elevated levels of thyroid-stimulating hormone and thyroid auto-antibodies compared to healthy individuals, with a 4.7 times greater risk of thyroid dysfunction among alopecia areata patients.

In this study, tofacitinib showed a mixed response in treating refractory alopecia areata, with some patients experiencing complete or partial hair regrowth and others showing no response, particularly those with alopecia universalis.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

This review discusses cardiovascular risks associated with androgen deprivation therapy in prostate cancer patients and highlights ongoing research, including the potential reduced COVID-19 susceptibility, but reports no new results.

This article discusses the impact of PROTACs technology in transforming drug discovery with its novel degradation mechanism, but it reports no new experimental findings.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

This study found that tofacitinib effectively induced hair regrowth in 62.2% of severe alopecia areata patients in Saudi Arabia after six months, with higher baseline Severity of Alopecia Tool scores and past steroid use linked to reduced response.

In this study, a taurine-based ionic liquid was developed to effectively penetrate the skin barrier and deliver antioxidants to hair follicles, reducing oxidative stress and promoting hair regrowth in an androgenic alopecia animal model.

Mini pulse corticosteroid therapy with oral dexamethasone is effective and has fewer side effects for treating extensive alopecia areata.

This review discusses the toxicities associated with antibody-drug conjugates in breast cancer treatment and proposes strategies for monitoring and managing these adverse effects, but it reports no new clinical results.

In this case study, a 29-year-old man with alopecia areata experienced satisfactory hair regrowth after five months of combined intralesional triamcinolone acetonide and platelet-rich plasma therapy.

This study found that dabrafenib was well tolerated and led to durable responses in patients with BRAF-mutant differentiated thyroid carcinoma, with a median progression-free survival of 11.3 months.

This study found that oral tofacitinib achieved significant hair regrowth in children with moderate to severe alopecia areata, with 72.2% reaching a 75% improvement and 52.8% achieving complete regrowth, though some patients did not respond and further research is needed on the treatment's long-term effects.

In this study, 40% of alopecia areata patients using topical 2% tofacitinib ointment achieved greater than 50% improvement in hair regrowth after six months, showing significant efficacy compared to controls, with no serious adverse effects reported.

This review provides a synopsis of 53 cases of temporal triangular alopecia, noting its frequent detection in early childhood and potential association with congenital diseases, but it reports no new clinical findings.

A deep learning model was developed to help diagnose trichothiodystrophy by analyzing hair patterns.

This study found that ATR-FTIR spectroscopy combined with machine learning effectively differentiated alopecia areata patients from healthy controls with an AUC of 0.85, and also showed promise in predicting treatment response, particularly through alterations in the Amide I band.

Some people with chronic hair loss may have thyroid autoimmunity.

This study found that tenuazonic acid from Alternaria alternata can cause significant damage to vital organs in mice at low doses and highlights the need for regulatory measures to manage its risk in agricultural products.

In this retrospective study conducted at a trichology clinic, the off-label use of upadacitinib for at least 24 weeks was found to have a promising efficacy and safety profile for treating severe alopecia areata in adolescents.